clopidogrel taw pharma (previously clopidogrel mylan)
taw pharma (ireland) limited - klopidogreelin hydrokloridi - peripheral vascular diseases; stroke; myocardial infarction; acute coronary syndrome - antitromboottiset aineet - , , , , secondary prevention of atherothrombotic events, , clopidogrel is indicated in: , - adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease. , - adult patients suffering from acute coronary syndrome:, - non-st segment elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa). , - st segment elevation acute myocardial infarction, in combination with asa in medically treated patients eligible for thrombolytic therapy. , , in patients with moderate to high-risk transient ischaemic attack (tia) or minor ischaemic stroke (is), clopidogrel in combination with asa is indicated in:, - adult patients with moderate to high-risk tia (abcd2 score ≥4) or minor is (nihss ≤3) within 24 hours of either the tia or is event. , , prevention of atherothrombotic and thromboembolic events in atrial fibrillation, in adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for treatment with vitamin k antagonists (vka) and who have a low bleeding risk, clopidogrel is indicated in combination with asa for the prevention of atherothrombotic and thromboembolic events, including stroke. , , for further information please refer to section 5. , , ,.
lanzo 30 mg rakeet oraalisuspensiota varten
wyeth lederle nordiska ab - lansoprazolum - rakeet oraalisuspensiota varten - 30 mg - lansopratsoli
mylotarg
wyeth europa ltd - gemtutsumab-ozogamisiini - leukemia, myeloidi, akuutti - antineoplastiset aineet - re-induktio hoito cd33-positiivisia aml aikuisten potilaiden ensimmäinen relapsivaihe, jotka eivät ole ehdokkaita muissa intensiivinen uudelleen induktio solunsalpaajahoito (e. korkea-annos ara-c) ja sen on täytettävä ainakin yksi seuraavista kriteereistä: kesto ensimmäisen remission 60 vuotta.
methotrexate pfizer 100 mg/ml infuusiokonsentraatti, liuosta varten
pfizer oy pfizer oy - methotrexatum - infuusiokonsentraatti, liuosta varten - 100 mg/ml - metotreksaatti
pamifos 3 mg/ml infuusiokonsentraatti, liuosta varten
medac gesellschaft fÜr klinische spezialprÄparate mbh - pamidronic acid - infuusiokonsentraatti, liuosta varten - 3 mg/ml - pamidronaatti
limbitrol 12,5 mg / 5 mg kapseli, kova
viatris oy - chlordiazepoxide, amitriptyline hydrochloride - kapseli, kova - 12,5 mg / 5 mg - amitriptyliini ja psyykenlääke
librax 5 mg / 2,5 mg tabletti, päällystetty
viatris oy - clidinium bromide, chlordiazepoxide - tabletti, päällystetty - 5 mg / 2,5 mg - klidiini ja psyykenlääke
serdolect 4 mg tabletti, kalvopäällysteinen
h. lundbeck a/s - sertindole - tabletti, kalvopäällysteinen - 4 mg - sertindoli
serdolect 12 mg tabletti, kalvopäällysteinen
h. lundbeck a/s - sertindole - tabletti, kalvopäällysteinen - 12 mg - sertindoli
serdolect 16 mg tabletti, kalvopäällysteinen
h. lundbeck a/s - sertindole - tabletti, kalvopäällysteinen - 16 mg - sertindoli